Post-Bariatric Hypoglycemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major post-bariatric hypoglycemia markets are expected to exhibit a CAGR of 5.28% during 2024-2034.
The post-bariatric hypoglycemia market has been comprehensively analyzed in IMARC's new report titled "Post-Bariatric Hypoglycemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post-bariatric hypoglycemia refers to a metabolic condition that can develop after weight loss surgery, such as gastric bypass or sleeve gastrectomy. It is characterized by recurrent episodes of low blood sugar levels, typically occurring 1 to 3 hours after meals. These episodes of hypoglycemia can lead to a range of symptoms, including dizziness, confusion, irritability, sweating, shakiness, and, in severe cases, loss of consciousness. The diagnosis of this ailment can be challenging as signs can be non-specific and overlap with several other post-operative complications or conditions. However, the healthcare professional might perform a comprehensive evaluation of the patient's medical history, indications, and blood sugar levels. Glucose monitoring during fasting and after meals is also recommended to identify the presence of low blood sugar episodes. Additionally, various tests to measure insulin levels and numerous other hormonal factors may be conducted to better recognize the underlying mechanisms contributing to the condition.
The escalating incidences of post-operative complications following bariatric surgery, particularly concerning the rapid insulin release resulting in low blood sugar, are primarily driving the post-bariatric hypoglycemia market. In addition to this, the inflating utilization of effective medications, such as glucagon-like peptide-1 (GLP-1) agonists, diazoxide, and somatostatin analogs for managing the condition and mitigating its impact is creating a positive outlook for the market. Moreover, the widespread adoption of nutritional counseling and personalized meal plans, which aid in stabilizing blood sugar fluctuations and promoting optimal glucose management, is further bolstering the market growth. Apart from this, the rising usage of novel therapeutic approaches like pancreatic islet transplantation, since it involves implanting insulin-producing cells to restore glucose equilibrium and enhance the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of continuous glucose monitoring systems that have revolutionized patient care by allowing real-time tracking of blood sugar levels and enabling timely interventions to avert hypoglycemic episodes, is also augmenting the market growth. Furthermore, the increasing application of advanced medical technologies, such as closed-loop insulin delivery systems, which improve treatment adherence and reduce the likelihood of neglecting glucose management tasks, is expected to drive the post-bariatric hypoglycemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the post-bariatric hypoglycemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-bariatric hypoglycemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-bariatric hypoglycemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post-bariatric hypoglycemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post-bariatric hypoglycemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post-bariatric hypoglycemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post-bariatric hypoglycemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post-bariatric hypoglycemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post-bariatric hypoglycemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with post-bariatric hypoglycemia across the seven major markets?
What is the size of the post-bariatric hypoglycemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post-bariatric hypoglycemia?
What will be the growth rate of patients across the seven major markets?
Post-Bariatric Hypoglycemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post-bariatric hypoglycemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-bariatric hypoglycemia market?
What are the key regulatory events related to the post-bariatric hypoglycemia market?
What is the structure of clinical trial landscape by status related to the post-bariatric hypoglycemia market?
What is the structure of clinical trial landscape by phase related to the post-bariatric hypoglycemia market?
What is the structure of clinical trial landscape by route of administration related to the post-bariatric hypoglycemia market?
The post-bariatric hypoglycemia market has been comprehensively analyzed in IMARC's new report titled "Post-Bariatric Hypoglycemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post-bariatric hypoglycemia refers to a metabolic condition that can develop after weight loss surgery, such as gastric bypass or sleeve gastrectomy. It is characterized by recurrent episodes of low blood sugar levels, typically occurring 1 to 3 hours after meals. These episodes of hypoglycemia can lead to a range of symptoms, including dizziness, confusion, irritability, sweating, shakiness, and, in severe cases, loss of consciousness. The diagnosis of this ailment can be challenging as signs can be non-specific and overlap with several other post-operative complications or conditions. However, the healthcare professional might perform a comprehensive evaluation of the patient's medical history, indications, and blood sugar levels. Glucose monitoring during fasting and after meals is also recommended to identify the presence of low blood sugar episodes. Additionally, various tests to measure insulin levels and numerous other hormonal factors may be conducted to better recognize the underlying mechanisms contributing to the condition.
The escalating incidences of post-operative complications following bariatric surgery, particularly concerning the rapid insulin release resulting in low blood sugar, are primarily driving the post-bariatric hypoglycemia market. In addition to this, the inflating utilization of effective medications, such as glucagon-like peptide-1 (GLP-1) agonists, diazoxide, and somatostatin analogs for managing the condition and mitigating its impact is creating a positive outlook for the market. Moreover, the widespread adoption of nutritional counseling and personalized meal plans, which aid in stabilizing blood sugar fluctuations and promoting optimal glucose management, is further bolstering the market growth. Apart from this, the rising usage of novel therapeutic approaches like pancreatic islet transplantation, since it involves implanting insulin-producing cells to restore glucose equilibrium and enhance the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of continuous glucose monitoring systems that have revolutionized patient care by allowing real-time tracking of blood sugar levels and enabling timely interventions to avert hypoglycemic episodes, is also augmenting the market growth. Furthermore, the increasing application of advanced medical technologies, such as closed-loop insulin delivery systems, which improve treatment adherence and reduce the likelihood of neglecting glucose management tasks, is expected to drive the post-bariatric hypoglycemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the post-bariatric hypoglycemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-bariatric hypoglycemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-bariatric hypoglycemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the post-bariatric hypoglycemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the post-bariatric hypoglycemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current post-bariatric hypoglycemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the post-bariatric hypoglycemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the post-bariatric hypoglycemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the post-bariatric hypoglycemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with post-bariatric hypoglycemia across the seven major markets?
What is the size of the post-bariatric hypoglycemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of post-bariatric hypoglycemia?
What will be the growth rate of patients across the seven major markets?
Post-Bariatric Hypoglycemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for post-bariatric hypoglycemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-bariatric hypoglycemia market?
What are the key regulatory events related to the post-bariatric hypoglycemia market?
What is the structure of clinical trial landscape by status related to the post-bariatric hypoglycemia market?
What is the structure of clinical trial landscape by phase related to the post-bariatric hypoglycemia market?
What is the structure of clinical trial landscape by route of administration related to the post-bariatric hypoglycemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST-BARIATRIC HYPOGLYCEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POST-BARIATRIC HYPOGLYCEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST-BARIATRIC HYPOGLYCEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POST-BARIATRIC HYPOGLYCEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST-BARIATRIC HYPOGLYCEMIA - UNMET NEEDS
10 POST-BARIATRIC HYPOGLYCEMIA - KEY ENDPOINTS OF TREATMENT
11 POST-BARIATRIC HYPOGLYCEMIA - MARKETED PRODUCTS
11.1 List of Post-Bariatric Hypoglycemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 POST-BARIATRIC HYPOGLYCEMIA - PIPELINE DRUGS
12.1 List of Post-Bariatric Hypoglycemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Pasireotide - RECORDATI
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Mizagliflozin - Vogenx
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Avexitide - Eiger BioPharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POST-BARIATRIC HYPOGLYCEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POST-BARIATRIC HYPOGLYCEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POST-BARIATRIC HYPOGLYCEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Post-Bariatric Hypoglycemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Post-Bariatric Hypoglycemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Post-Bariatric Hypoglycemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Post-Bariatric Hypoglycemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Post-Bariatric Hypoglycemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Post-Bariatric Hypoglycemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Post-Bariatric Hypoglycemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Post-Bariatric Hypoglycemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
16 POST-BARIATRIC HYPOGLYCEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POST-BARIATRIC HYPOGLYCEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POST-BARIATRIC HYPOGLYCEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POST-BARIATRIC HYPOGLYCEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POST-BARIATRIC HYPOGLYCEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POST-BARIATRIC HYPOGLYCEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POST-BARIATRIC HYPOGLYCEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POST-BARIATRIC HYPOGLYCEMIA - UNMET NEEDS
10 POST-BARIATRIC HYPOGLYCEMIA - KEY ENDPOINTS OF TREATMENT
11 POST-BARIATRIC HYPOGLYCEMIA - MARKETED PRODUCTS
11.1 List of Post-Bariatric Hypoglycemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 POST-BARIATRIC HYPOGLYCEMIA - PIPELINE DRUGS
12.1 List of Post-Bariatric Hypoglycemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Pasireotide - RECORDATI
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Mizagliflozin - Vogenx
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Avexitide - Eiger BioPharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POST-BARIATRIC HYPOGLYCEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POST-BARIATRIC HYPOGLYCEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POST-BARIATRIC HYPOGLYCEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Post-Bariatric Hypoglycemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Post-Bariatric Hypoglycemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Post-Bariatric Hypoglycemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Post-Bariatric Hypoglycemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Post-Bariatric Hypoglycemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Post-Bariatric Hypoglycemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Post-Bariatric Hypoglycemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Post-Bariatric Hypoglycemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Post-Bariatric Hypoglycemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Post-Bariatric Hypoglycemia - Access and Reimbursement Overview
16 POST-BARIATRIC HYPOGLYCEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POST-BARIATRIC HYPOGLYCEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POST-BARIATRIC HYPOGLYCEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
